Certara, Inc.CERTEarnings & Financial Report
Certara is a global leader in biopharmaceutical software and consulting services, specializing in modeling, simulation, and regulatory science solutions. It serves pharmaceutical companies, biotech firms and healthcare stakeholders across all drug development stages, helping accelerate new therapy launches, lower R&D risks and cut overall development costs.
CERT Q1 FY2026 Key Financial Metrics
Revenue
$106.9M
Gross Profit
$65.3M
Operating Profit
$37.3M
Net Profit
$-8.8M
Gross Margin
61.1%
Operating Margin
34.9%
Net Margin
-8.2%
YoY Growth
0.8%
EPS
$-0.06
Certara, Inc. Q1 FY2026 Financial Summary
Certara, Inc. reported revenue of $106.9M (up 0.8% YoY) for Q1 FY2026, with a net profit of $-8.8M (down 287.2% YoY) (-8.2% margin). Cost of goods sold was $41.6M, operating expenses totaled $28.0M.
Key Financial Metrics
| Total Revenue | $106.9M |
|---|---|
| Net Profit | $-8.8M |
| Gross Margin | 61.1% |
| Operating Margin | 34.9% |
| Report Period | Q1 FY2026 |
Certara, Inc. Annual Revenue by Year
Certara, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $418.8M).
Certara, Inc. Quarterly Revenue & Net Profit History
Certara, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $106.9M | +0.8% | $-8.8M | -8.2% |
| Q4 FY2025 | $103.6M | +3.3% | $-5.9M | -5.7% |
| Q3 FY2025 | $104.6M | +10.3% | $1.5M | 1.5% |
| Q2 FY2025 | $104.6M | +12.1% | $-2.0M | -1.9% |
| Q1 FY2025 | $106.0M | +9.7% | $4.7M | 4.5% |
| Q4 FY2024 | $100.4M | +14.0% | $6.6M | 6.6% |
| Q3 FY2024 | $94.8M | +10.8% | $-1.4M | -1.4% |
| Q2 FY2024 | $93.3M | +3.2% | $-12.6M | -13.5% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $93.3M | $94.8M | $100.4M | $106.0M | $104.6M | $104.6M | $103.6M | $106.9M |
| YoY Growth | 3.2% | 10.8% | 14.0% | 9.7% | 12.1% | 10.3% | 3.3% | 0.8% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.54B | $1.54B | $1.58B | $1.56B | $1.54B | $1.54B | $1.56B | $1.50B |
| Liabilities | $496.2M | $489.8M | $516.4M | $476.7M | $472.9M | $471.0M | $493.8M | $483.3M |
| Equity | $1.04B | $1.05B | $1.06B | $1.08B | $1.07B | $1.06B | $1.06B | $1.02B |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $9.8M | $17.0M | $49.4M | $17.4M | $17.8M | $32.3M | $28.8M | $11.7M |